DPYD and colorectal carcinoma: The results of our meta-analysis showed significant correlations between DPYD genetic polymorphisms and the incidence of adverse drug events in CRC patients receiving 5-FU chemotherapy, including marrow suppression, gastrointestinal reaction, and hand-foot syndrome, implying that DPYD genetic polymorphisms may be significantly related to toxicity of 5-FU chemotherapy in CRC.